Dechert advised CTRS on the deal.
CTRS, a French pharmaceutical company which specializes in rare diseases, executed its OBO transaction in which Mérieux Equity Partners, a global investment platform specialized in the healthcare sector, has acquired a stake in the group.
This new financial partnership will enable CTRS to strengthen its leading position in the field of rare diseases.
Dechert’s multi-disciplinary team included on Corporate/M&A: Alain Decombe, partner and Xavier Leroux, senior associate, assisted by Benhouda Derradji and Charlotte Torck, associates; on Tax structuring aspects: Sabina Comis, partner, assisted by Etienne Bimbeau, associate; on Financing: Guénaëlle Taroni and Marianne Sajus, associates; on Regulatory: Sophie Pelé, national partner.
Involved fees earner: Etienne Bimbeau – Dechert; Sabina Comis – Dechert; Alain Decombe – Dechert; Benhouda Derradji – Dechert; Xavier Leroux – Dechert; Sophie Pelé – Dechert; Marianne Sajus – Dechert; Guénaelle Taroni – Dechert; Charlotte Torck – Dechert;
Law Firms: Dechert;